An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies-Reference-Cited by-同舟云学术

An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Published:2022-06-14 Issue:7 Volume:5 Page:2200008
ISSN:2366-3987
Container-title:Advanced Therapeutics
language:en
Short-container-title:Advanced Therapeutics

Author:

Eltahir Mohamed¹^ORCID,Laurén Ida¹^ORCID,Lord Martin¹,Chourlia Aikaterini¹,Dahllund Leif²³,Olsson Anders²³,Saleh Aljona⁴,Ytterberg A. Jimmy⁴,Lindqvist Annika⁴,Andersson Oskar²³,Persson Helena²³,Mangsbo Sara M.¹

Affiliation:

1. Department of Pharmacy Science for Life Laboratory Uppsala University Husargatan 3 Uppsala Box 580 751 24 Sweden

2. SciLifeLab Drug Discovery and Development Science for Life Laboratory – Stockholm Tomtebodavägen 23A Solna 171 65 Sweden

3. School of Engineering Sciences in Chemistry Biotechnology and Health Royal Institute of Technology (KTH) Tomtebodavägen 23A Solna 65 Sweden

4. Department of Pharmacy SciLifeLab Drug Discovery and Development Platform Uppsala University Husargatan 3 Uppsala Box 580 751 24 Sweden

Publisher

Wiley

Subject

Pharmacology (medical),Biochemistry (medical),Genetics (clinical),Pharmaceutical Science,Pharmacology,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adtp.202200008

Reference52 articles.

1. Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery

2. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications

3. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses

4. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition

5. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8+ and CD4+ T Cells

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation CD40 agonists for cancer immunotherapy;Expert Opinion on Biological Therapy;2024-05-03

2. Abstract 2929: Modular peptide cargo delivery by targeting CD40 enables ligandome driven, precision immunotherapy via the Adaptable Drug Affinity Conjugate (ADAC™) technology;Cancer Research;2023-04-04